全文获取类型
收费全文 | 6569篇 |
免费 | 474篇 |
国内免费 | 154篇 |
专业分类
耳鼻咽喉 | 92篇 |
儿科学 | 94篇 |
妇产科学 | 106篇 |
基础医学 | 336篇 |
口腔科学 | 66篇 |
临床医学 | 330篇 |
内科学 | 569篇 |
皮肤病学 | 61篇 |
神经病学 | 116篇 |
特种医学 | 503篇 |
外国民族医学 | 3篇 |
外科学 | 1272篇 |
综合类 | 454篇 |
预防医学 | 63篇 |
眼科学 | 35篇 |
药学 | 188篇 |
1篇 | |
中国医学 | 40篇 |
肿瘤学 | 2868篇 |
出版年
2024年 | 11篇 |
2023年 | 105篇 |
2022年 | 190篇 |
2021年 | 269篇 |
2020年 | 237篇 |
2019年 | 236篇 |
2018年 | 253篇 |
2017年 | 197篇 |
2016年 | 276篇 |
2015年 | 263篇 |
2014年 | 406篇 |
2013年 | 465篇 |
2012年 | 338篇 |
2011年 | 312篇 |
2010年 | 234篇 |
2009年 | 331篇 |
2008年 | 353篇 |
2007年 | 357篇 |
2006年 | 306篇 |
2005年 | 265篇 |
2004年 | 219篇 |
2003年 | 170篇 |
2002年 | 153篇 |
2001年 | 153篇 |
2000年 | 112篇 |
1999年 | 114篇 |
1998年 | 120篇 |
1997年 | 86篇 |
1996年 | 58篇 |
1995年 | 68篇 |
1994年 | 65篇 |
1993年 | 47篇 |
1992年 | 48篇 |
1991年 | 31篇 |
1990年 | 25篇 |
1989年 | 40篇 |
1988年 | 37篇 |
1987年 | 18篇 |
1986年 | 34篇 |
1985年 | 30篇 |
1984年 | 28篇 |
1983年 | 16篇 |
1982年 | 24篇 |
1981年 | 26篇 |
1980年 | 25篇 |
1979年 | 19篇 |
1978年 | 8篇 |
1977年 | 6篇 |
1976年 | 7篇 |
1972年 | 2篇 |
排序方式: 共有7197条查询结果,搜索用时 15 毫秒
1.
2.
Breast carcinoma is a major cause of morbidity and mortality in women. The study of bone pathologies presents considerable potential in anthropology, paleopathology, forensic science and medicine. In this paper, we present and discuss metastatic lesions found in the skeletons of known individuals from the CAL Milano Cemetery Skeletal Collection, clinically diagnosed with breast cancer during life. Fourteen skeletons from a contemporary and identified collection were macroscopically studied and metastases were identified by comparison with clinical literature. As a result, bone metastases were observed in 43% of the study sample. They were located most commonly on the ribs (28.1%), pelvic girdle (19.8%), vertebrae (15.6%), skull (15.6%), scapulae (10.2%) as well as proximal segment of the femora (8.4%) and humeri (2.4%) respectively, favoring sites of high vascularization. The majority of the lesions were osteolytic, although osteoblastic and mixed metastases did occur. Osteolytic metastases appear as coalescent porosity or round to oval perforating lesions on bones with denticulated margins and pitted surrounding bone, whereas osteoblastic metastases thickened the existing trabecula (spongiosclerosis). Mixed metastases were perforating lytic lesions exposing the osteoblastic activity in the underlying trabecular bone. These results, consistent with the data from the literature, strengthen the diagnostic criteria for metastases and illustrate the aspect of bone metastases in breast carcinoma. 相似文献
3.
4.
5.
While once considered as incurable systemic disease, treatment options for liver metastases have increased over the last 30 years and safety has improved dramatically, such that for a selected group of patients the hope of cure can now be offered with radical treatment, and low morbidity interventions can be offered which prolong survival, even in patients with more widely disseminated disease. Advances have been made in selection and surgical technique for liver resection and several adjuncts to resection now exist in the form of portal vein embolization, thermal ablation and targeted drug or radiotherapy delivery options. A natural consequence of these developments has been the delivery of services within fewer specialist units, with the result that later complications of therapy may present to local hospitals, rather than directly to the specialist centres. This article will describe the current common liver-directed therapies and outline the presentation and management of their complications. 相似文献
6.
Marco Maruzzo Umberto Basso Eugenio Borsatti Laura Evangelista Filippo Alongi Orazio Caffo Francesca Maines Sara Galuppo Rocco De Vivo Fable Zustovich Dario Palleschi Andrea Zivi Teodoro Sava Mariella Sorarù Roberto Iacovelli Maurizio Nicodemo Susanne Baier Lucia Fratino Vittorina Zagonel 《Clinical genitourinary cancer》2019,17(1):e187-e194
Background
Radium 223 was introduced for metastatic castration-resistant prostate cancer based on the results of a randomized controlled trial showing risk reduction for death and skeletal events. Our aim was to evaluate the outcome of patients receiving radium 223 in a real-world setting.Patients and Methods
We conducted a multicenter retrospective analysis in the Triveneto region of Italy.Results
One hundred fifty-eight patients received radium 223 in our region. After a median follow-up of 9.5 months, 75 patients died. The median overall survival (OS) was 14.2 months, and the median progression-free survival (PFS) was 6.2 months. Seventy-one (45%) patients achieved progression as best response. Thirty-seven (23%) patients stopped the treatment early because of progression. Eastern Cooperative Oncology Group performance status was prognostic for OS (18.4 vs. 12.3 vs. 7.5 months; 0 vs. 1, P = .0062; 0 vs. 2, P = .0002), whereas previous prostatectomy or docetaxel exposure were not. A neutrophil to lymphocytes ratio ≥ 3 significantly impacted OS (18.1 vs. 9.7 months; P < .001) and slightly impacted PFS (6.6 vs. 5.6 months; P = .05). Patients with a baseline alkaline phosphatase (ALP) value ≥ 220 U/L had worse OS and PFS (24.1 vs. 10.5 months; 7.2 vs. 5.5 months; P < .001). Patients with changes in ALP value achieved better OS (P = .029) and PFS (P = .002). There was no difference according to the line of therapy (0 vs. ≥ 1; P = .490). The main grade 3/4 toxicities were anemia, asthenia, and thrombocytopenia.Conclusion
This large real-world report confirms comparable OS and PFS data when compared with the pivotal study, as well as the predictive role of ALP and neutrophil to lymphocytes ratio. The definition of the optimal position of radium 223 in the treatment of metastatic castration-resistant prostate cancer has still to be defined. 相似文献7.
目的评估增强减影在脊椎转移瘤MR I中的应用价值。方法50例脊椎转移瘤病人进行MR I增强扫描,对比剂采用Gd-DTPA(0.1 mmol/kg),然后用T1W I增强后的图像与增强前的图像进行减影。通过对比噪声比(CNR)、信噪比(SNR)以及肿瘤边界清晰程度的比较,对MR I减影与否进行评估。结果MR I对比增强减影图像比传统的T1W I增强图像显示更清晰、更直观。所有脊椎转移瘤图像MR I减影的CNR和SNR比常规T1W I增强图像的CNR和SNR高。MR I减影CNR为155.05±24.73(x±SD),常规T1W I增强图像的CNR为11.11±14.26(t=35.65,Ρ<0.001)。MR I减影SNR为192.82±32.89(x±SD),常规T1W I增强图像的SNR为46.03±28.22(t=23.95,Ρ<0.001))。MR I对比增强减影图像比传统的T1W I增强图像能更好地显示脊椎转移瘤的边界和侵犯情况(2χ=29.34,Ρ<0.005)。结论MR I增强减影为探查和评估脊椎转移瘤提供了一个新的诊断方法。 相似文献
8.
P Sundaresan R Yeghiaian-Alvandi V Gebski 《Journal of Medical Imaging and Radiation Oncology》2010,54(1):69-75
Palliative whole brain radiotherapy (WBRT) is often recommended in the management of multiple brain metastases. Allowing for WBRT waiting time, duration of the WBRT course and time to clinical response, it may take 6 weeks from the point of initial assessment for a benefit from WBRT to manifest. Patients who die within 6 weeks (‘early death’) may not benefit from WBRT and may instead experience a decline in quality of life. This study aimed to develop a prognostic index (PI) that identifies the subset of patients with lung cancer with multiple brain metastases who may not benefit from WBRT because of ‘early death’. The medical records of patients with lung cancer who had WBRT recommended for multiple brain metastases over a 10-year period were retrospectively reviewed. Patients were classified as either having died within 6 weeks or having lived beyond 6 weeks. Potential prognostic indicators were evaluated for correlation with ‘early death’. A PI was constructed by modelling the survival classification to determine the contribution of these factors towards shortened survival. Of the 275 patients recommended WBRT, 64 (23.22%) died within 6 weeks. The main prognostic factor predicting early death was Eastern Cooperative Oncology Group (ECOG) status >2. Patients with a high PI score (>13) were at higher risk of ‘early death’. Twenty-three per cent of patients died prior to benefit from WBRT. ECOG status was the most predictive for ‘early death’. Other factors may also contribute towards a poor outcome. With further refinement and validation, the PI could be a valuable clinical decision tool. 相似文献
9.
Kimberly A. Varker Edward W. Martin Dori Klemanski Bryan Palmer Manisha H. Shah Mark Bloomston 《Journal of gastrointestinal surgery》2007,11(12):1680-1685
Background
Transarterial chemoemobolization (TACE) is commonly used to treat metastatic carcinoid tumors; however, the management of
progressive disease is less clear. We sought to determine if patients with disease progression after TACE would benefit from
repeat TACE.
Methods
The records of 27 patients undergoing repeat TACE for radiologic or symptomatic progression after TACE for metastatic carcinoid
were reviewed and compared to 122 undergoing first TACE. Overall and progression-free survivals were estimated by the Kaplan–Meier
method.
Results
Mean disease-free interval after first TACE was 11.8 months. Radiologic response was observed in 61% compared to 82% after
first TACE (p = 0.058); hormone response in 64% compared to 80% (p = 0.159); and symptomatic response in 77% compared to 92% (p = 0.053). The complication rate after repeat TACE was lower than after first TACE (p = 0.03). Median overall survival was similar after repeat (28.1 months) and first TACE (33.3 months) (p = 0.53). Progression-free survival was shorter after repeat TACE but not significantly so. No factor examined could predict
survival after repeat TACE.
Conclusion
Repeat TACE for patients with hepatic carcinoid metastases failing first TACE or having evidence of disease progression is
safe and offers a viable treatment option.
Presented at the 48th Annual Meeting of The Society for Surgery of the Alimentary Tract, Washington, DC, May, 2007. 相似文献
10.
CT导引经皮穿刺注射无水乙醇治疗溶骨性骨转移瘤 总被引:1,自引:1,他引:0
目的探讨CT导引下经皮穿刺注射无水乙醇(CT~PEI)治疗溶骨性骨转移瘤的价值及安全性。方法对17例骨转移瘤患者(25个病灶)采用CT—PEI治疗,使用无水乙醇和超化碘油10:1的混合剂,用CT精确定位、准确穿刺瘤灶并密切监控无水乙醇弥散情况及用量,以减少并发症。对接近椎管及椎间孔的病灶,采用利多卡因实验性治疗以避免严重并发症。术前及术后定期CT检查,3例病人行同位素骨扫描检查,与治疗前检查进行对照研究。对患者随访3~30个月观察其临床疗效。结果所有患者经1次CT—PEI治疗后,疼痛即明显减轻,经2~3次CT-PEI治疗后疼痛完全缓解(CR)16例(24处病灶),疼痛部分缓解(PR)1例。术后随访3个月时,23处病灶内肿瘤组织均发生坏死,被高密度碘油混合液均匀浸润。其中,9处病灶体积缩小。随访3~30个月,除1例因周边出现新的肿瘤浸润灶而再次出现疼痛,其余病例转移瘤处止痛效果无反复。所有病例无严重并发症。结论CT—PEI是一种治疗骨转移瘤有效、微创、安全、简便的方法,使骨转移瘤内肿瘤组织坏死,最大限度的杀灭肿瘤细胞,从而达到满意的止痛效果,明显改善恶性肿瘤溶骨性转移病人的生活质量。 相似文献